Octave Bioscience

Octave Bioscience Announces Strategic Investment from the Merck Global Health Innovation Fund to Transform Disease Measurement and Care for Patients with Neurodegenerative Diseases

Retrieved on: 
星期二, 十月 12, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Population health, Brain, Inflammation, Digital health, Health, Biology, Digital, Neurology, Decision-making, MS, Physician, Spine, List of life sciences, GHI, Industry, HIV disease progression rates, Neurodegeneration, Population, Investment, MRI, Multiple sclerosis, Founder, CNS, Patient, View, Pharmaceutical industry, Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, the Octave Bioscience Comprehensive Care Platform, Octave Bioscience, Merck Global Health Innovation Fund, THE OCTAVE BIOSCIENCE COMPREHENSIVE CARE PLATFORM, OCTAVE BIOSCIENCE, MERCK GLOBAL HEALTH INNOVATION FUND

Octave Bioscience , the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, announced today that the Merck Global Health Innovation Fund ( Merck GHIF ) has made a strategic investment in Octave to further advance its industry-leading capabilities in neurodegenerative diseases.

Key Points: 
  • Octave Bioscience , the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, announced today that the Merck Global Health Innovation Fund ( Merck GHIF ) has made a strategic investment in Octave to further advance its industry-leading capabilities in neurodegenerative diseases.
  • Octave Bioscience is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS.
  • Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis as well as a full range of neurodegenerative diseases.
  • Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy.

Octave Bioscience Appoints Maital Shemesh-Rasmussen as Chief Commercial Officer

Retrieved on: 
星期三, 三月 17, 2021
Science, Other Science, Biotechnology, Research, Health, Medical devices, Hospitals, Other Health, Software, Programming languages, Application software, GNU Octave, Neurodegeneration, Tropical Storm Octave, the Octave Bioscience Comprehensive Care Platform, Octave Bioscience

Octave Bioscience, the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced that it has named Maital Shemesh-Rasmussen as Chief Commercial Officer (CCO).

Key Points: 
  • Octave Bioscience, the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced that it has named Maital Shemesh-Rasmussen as Chief Commercial Officer (CCO).
  • We are thrilled to welcome Maital to the Octave Bioscience team and we look forward to her leadership, experiences and insights in building out our commercial capabilities and preparing for early deployments, said William Hagstrom, Chief Executive Officer and Founder of Octave Bioscience.
  • Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis as well as a full range of neurodegenerative diseases.
  • Octave Bioscience is headquartered in Menlo Park, California.

Octave Bioscience Secures $32 Million Series B Financing

Retrieved on: 
星期四, 十二月 17, 2020
Data management, Health, Medical devices, Technology, Other Technology, General Health, Biotechnology, Senescence, Branches of biology, Programming languages, Software, GNU Octave, Degenerative disease, Neurodegeneration, Multiple Sclerosis, the Octave Bioscience Comprehensive Care Platform, Octave Bioscience, Northpond Ventures

Octave Bioscience , the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the completion of a $32 million Series B financing.

Key Points: 
  • Octave Bioscience , the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the completion of a $32 million Series B financing.
  • Neurodegenerative diseases represent a new and important frontier for innovation in the quest to address significant unmet needs and transform care, said William A. Hagstrom, Founder and CEO of Octave Bioscience.
  • Octave Bioscience is completing development of a comprehensive, first-in-class care management platform for neurodegenerative disease, beginning with MS.
  • Octave Bioscience was founded to deliver an end-to-end care management platform for multiple sclerosis as well as a full range of neurodegenerative diseases.